Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Noah A. Cohen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3947-2585; OpenAlex author ID A5033144345, A5040986338. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 4 papers · 2024: none · 2025: none · 2026: 3 papers

Papers 10

  1. Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18915-0↗
  2. ASO Author Reflections: Recognizing Regret: How Can We Improve Communication with Patients with Pancreatic Cancer. First author DOI 10.1245/s10434-025-18962-7↗
  3. ASO Visual Abstract: Assessing Clinical Factors and Communication Barriers Impacting Postoperative Regret in Patients with Pancreatic Cancer. Last author DOI 10.1245/s10434-026-19157-4↗
  4. Perineural Invasion of Pancreatic Ductal Adenocarcinoma is Associated with Early Recurrence after Neoadjuvant Therapy Followed by Resection. Last author DOI 10.1007/s00268-023-06983-w↗
  5. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  6. ASO Author Reflections: Timing of Systemic Therapy and Postoperative Morbidity in Resectable Pancreatic Ductal Adenocarcinoma and Distal Cholangiocarcinoma. First author DOI 10.1245/s10434-023-13581-6↗
  7. Surgical management of pancreatic ductal adenocarcinoma: a narrative review. Last author DOI 10.21037/tgh-23-27↗
  8. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. First author DOI 10.1002/jso.26735↗
  9. Surgical management of pancreatic cancer liver oligometastases. Last author DOI 10.1016/j.critrevonc.2022.103654↗
  10. Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001881↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Umut Sarpel · 5 shared papers, 2021–2026 · strength 0.97
  2. Rebekah Macfie · 3 shared papers, 2022–2023 · strength 0.73
  3. Judy Li · 1 shared paper, 2026 · strength 0.63
  4. Neha L. Lad · 2 shared papers, 2026 · strength 0.50
  5. Judy Li · 2 shared papers, 2026 · strength 0.50
  6. Camilo Correa‐Gallego · 2 shared papers, 2026 · strength 0.50
  7. Joshua Leinwand · 2 shared papers, 2026 · strength 0.50
  8. Elizabeth Gleeson · 2 shared papers, 2021–2023 · strength 0.30
  9. Elad Sarfaty · 1 shared paper, 2023 · strength 0.24
  10. Da Eun Cha · 1 shared paper, 2023 · strength 0.17
  11. Vinod P. Balachandran · 1 shared paper, 2022 · strength 0.13
  12. Anna M. Varghese · 1 shared paper, 2022 · strength 0.13
  13. Kevin C. Soares · 1 shared paper, 2022 · strength 0.13
  14. T. Peter Kingham · 1 shared paper, 2022 · strength 0.13
  15. Michael Ian D'Angelica · 1 shared paper, 2022 · strength 0.13
  16. Caitlin A. McIntyre · 1 shared paper, 2022 · strength 0.13
  17. Eileen Mary O'Reilly · 1 shared paper, 2022 · strength 0.13
  18. Jeffrey A. Drebin · 1 shared paper, 2022 · strength 0.13
  19. Eran Sadot · 1 shared paper, 2022 · strength 0.13
  20. Peter J. Allen · 1 shared paper, 2022 · strength 0.13
  21. William R. Jarnagin · 1 shared paper, 2022 · strength 0.13
  22. Kenneth H. Yu · 1 shared paper, 2022 · strength 0.13
  23. Alice Chia-Chi Wei · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.